RecruitingNCT06051890
Extended-release or under-the-tongue buprenorphine for people entering jail
About this title
Read the official source — NCT06051890Medication studyUnited StatesAddiction
Understand this study
- Listed locations
- Boston and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 2, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Not clearly listed
- Official registry ID
- NCT06051890
- Official title
Show the full official title
Assessing Optimal Extended-Release Buprenorphine (XRB) Initiation Points in Jail
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boston · Springfield · New Brunswick
1 more locations
- New York
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Does this study involve medication?
Yes. The study involves medication, including Extended-Release Buprenorphine (XRB) and Sublingual Buprenorphine (SLB).
Is this study still recruiting?
The registry lists this study as recruiting.
